On March 14, 2022 EVERSANA reported that virtually at BIO-Europe Spring, March 28-31, 2022 (Press release, EVERSANA, MAR 14, 2022, View Source [SID1234610066]). With over 40 clients and a growing number of engagements in Europe, EVERSANA is leading the way as the only end-to-end provider of commercialisation services that span all stages of the product life cycle to deliver long-term value for patients, physicians and payers .
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Join our team for virtual networking during BIO-Europe Spring or watch our experts speak during the following sessions.
Panel Discussion: How digital health technologies can support systemic change in healthcare
Monday, 28 March 2022 13:30 – 14:30Join EVERSANA’s Ed Cox. Executive Vice President, Strategic Alliances & Global Head of Digital Medicine and fellow panelists as they discuss how digital health technologies impact the patient’s healthcare experience, from how big data applications can help identify at-risk patients to feeding back RWE to inform the drug innovation process. The discussion will also touch on how these technologies can open new ways to provide access to therapeutics in underserved areas such as mental health and chronic diseases.
Panel Discussion: Early Trial Planning in Times of Pay-for-Performance Agreements & European HTA Harmonization
Wednesday, 30 March 2022 13:30 – 14:30
In this workshop, EVERSANA’s Mike Ryan, Executive Vice President, Europe and other industry experts will focus on innovative reimbursement for high-cost therapies in Europe. They will outline how mid-sized biotech companies can successfully bring their innovations into the European reimbursement systems through early study planning. Special emphasis is placed on the harmonization of the health technology assessment (HTA) procedures and the resulting study design requirements. Success factors for pay-for-performance models are also presented.